כניסה 
עקבו אחרינו בפייסבוק הבדלים בין גרסאות בדף "אורנסיה - Orencia"
מתוך ויקירפואה
| שורה 7: | שורה 7: | ||
|קישור למאגר משרד הבריאות1=[http://www.old.health.gov.il/units/pharmacy/trufot/Mucar_List.asp?p=1&Sr_Type=Activ&Y_Name=ABATACEPT&Letter=a&safa= "אורנסיה®"] | |קישור למאגר משרד הבריאות1=[http://www.old.health.gov.il/units/pharmacy/trufot/Mucar_List.asp?p=1&Sr_Type=Activ&Y_Name=ABATACEPT&Letter=a&safa= "אורנסיה®"] | ||
|סל הבריאות=כלול <hr> | |סל הבריאות=כלול <hr> | ||
| − | |מסגרת הכללה בסל='''עדכון סל התרופות 2012'''{{ש}}טיפול בדלקת פרקים מסוג polyarticular juvenile idiopathic arthritis | + | |מסגרת הכללה בסל='''עדכון סל התרופות 2012'''{{ש}}טיפול בדלקת פרקים מסוג polyarticular juvenile idiopathic arthritis <hr> |
|התוויות= Orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease modifying anti rheumatic drugs (DMARDs) including methotrexate (MTX) or a TNF-alpha inhibitor. A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate. Polyarticular juvenile idiopathic arthritis: Orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other DMARDs including at least one TNF inhibitor. Orencia has not been studied in children under 6 years old. | |התוויות= Orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease modifying anti rheumatic drugs (DMARDs) including methotrexate (MTX) or a TNF-alpha inhibitor. A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate. Polyarticular juvenile idiopathic arthritis: Orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other DMARDs including at least one TNF inhibitor. Orencia has not been studied in children under 6 years old. | ||
|קיים גם בתכשירים= | |קיים גם בתכשירים= | ||
גרסה מ־19:22, 15 בינואר 2012
| אורנסיה - Orencia | ||
|---|---|---|
| מרכיב פעיל | ABATACEPT | |
| קבוצה פרמקולוגית (ATC) | "SELECTIVE IMMUNOSUPPRESSIVE AGENTS" | |
| שם התרופה | "אורנסיה®" (קישור לדף התרופה במאגר משרד הבריאות) |
|
| סל הבריאות | כלול |
|
| מסגרת הכללה בסל | עדכון סל התרופות 2012 טיפול בדלקת פרקים מסוג polyarticular juvenile idiopathic arthritis |
|
התוויות |
Orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease modifying anti rheumatic drugs (DMARDs) including methotrexate (MTX) or a TNF-alpha inhibitor. A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate. Polyarticular juvenile idiopathic arthritis: Orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other DMARDs including at least one TNF inhibitor. Orencia has not been studied in children under 6 years old.
| |
| שם יצרן | BRISTOL MYERS SQUIBB SPA, ITALY | |
| שם בעל הרישום | BRISTOL-MYERS SQUIBB (ISRAEL) LIMITED | |